BioPharmSignal logoBioPharmSignal

Biotech News

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026

Structure Therapeutics (GPCR)Structure TherapeuticsCompany update

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming

Related news

GPCRStructure Therapeutics2026-09-03 11:30 EST

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

GPCRStructure Therapeutics2026-11-04 12:30 EST

Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference

KYMRKymera2026-09-01 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

AVTXAvalo Therapeutics2026-11-02 21:00 EST

Avalo Therapeutics to Participate in Upcoming Investor Conferences

KYTXKyverna Therapeutics2026-10-23 14:30 EST

Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026

KYTXKyverna Therapeutics2026-10-07 12:00 EST

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

RNACCartesian Therapeutics2026-09-03 11:00 EST

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

KYMRKymera2026-09-02 20:01 EST

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

NRIXNurix Therapeutics2026-09-01 12:00 EST

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

VERAVera Therapeutics2026-09-01 11:30 EST

Vera Therapeutics to Participate at Upcoming Investor Conferences

View all latest news

Structure Therapeutics

Structure-Based Metabolic Drug Discovery Structure Therapeutics develops oral small molecules against validated metabolic targets using structure-based drug design. Its franchise is intended to offer oral alternatives to injectable peptide therapies. Aleniglipron Aleniglipron is an oral GLP-1 receptor agonist in development for obesity...

Recent company news

GPCRStructure Therapeutics2026-11-04 12:30 EST

Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference

GPCRStructure Therapeutics2026-10-19 20:14 EST

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026

GPCRStructure Therapeutics2026-09-08 12:00 EST

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

GPCRStructure Therapeutics2026-09-03 11:30 EST

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Stock data

Close
19.08 USD
Market cap
2.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States